deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02821416

Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics (ARIA)

A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Multi-Centre Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics

Sponsor: AstraZeneca

Conditions Asthma
Interventions Benralizumab Placebo
Updated 24 times since 2017 Last updated: Dec 14, 2020 Started: Oct 11, 2016 Primary completion: Oct 22, 2019 Completion: Oct 22, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Asthma and is currently completed. AstraZeneca leads this study, which shows 24 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Mar 2017 · 59 days · monthly snapshot~Mar 2017 – ~May 2017 · 2 months · monthly snapshot~May 2017 – ~Jul 2017 · 2 months · monthly snapshot~Jul 2017 – ~Oct 2017 · 3 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Jun 2019 · 3 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Dec 2021 · 10 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Feb 2021 — Dec 2021 [monthly]

    Completed PHASE3

▶ Show 19 earlier versions

  1. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE3

  2. Nov 2019 — Jan 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Sep 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Mar 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  6. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  7. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  8. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  9. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  10. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  11. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  12. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  13. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  14. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  15. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  16. Jul 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  17. May 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  18. Mar 2017 — May 2017 [monthly]

    Recruiting PHASE3

  19. Jan 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

    First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations